GLP-1 Medications and Heart Health: What the SELECT Trial and 2026 Guidance Show
GLP-1 medications are best known for weight loss, but some also have published evidence of cardiovascular benefit. The SELECT trial found that in adults with overweight or obesity and preexisting cardiovascular disease, semaglutide reduced major adverse cardiovascular events by about 20% compared with placebo. Here is what the evidence and the latest guidance show.
Key Points
- The SELECT trial found semaglutide reduced major cardiovascular events by about 20% (hazard ratio 0.80) in adults without diabetes
- The WHO issued its first global guideline on GLP-1 medicines for obesity in December 2025
- ADA 2026 Standards of Care name GLP-1 receptor agonists as preferred weight-management pharmacotherapy for many people with diabetes and overweight or obesity
- The strongest weight-loss results are seen with semaglutide and tirzepatide, with lifestyle support recommended alongside
- Any use of these medications requires a medical evaluation and ongoing supervision
What the SELECT Trial Found
The SELECT trial, published in the New England Journal of Medicine in December 2023, studied once-weekly semaglutide 2.4 mg in more than 17,600 adults with overweight or obesity and established cardiovascular disease, but without diabetes. Over a median follow-up of about 34 months, the primary composite endpoint of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group, a 20% relative risk reduction (hazard ratio 0.80).
That means the medication did more than help with weight: it was associated with fewer serious cardiovascular events in this specific population. The study was industry-funded, which is normal for large cardiovascular outcome trials, and the findings apply to the study population, not automatically to every person who takes the medication.
What the 2025-2026 Guidance Says
In December 2025 the World Health Organization issued its first global guideline on GLP-1 medicines for treating obesity in adults, making conditional recommendations for the long-term use of liraglutide, semaglutide and tirzepatide in adults with obesity, alongside intensive behavioral and lifestyle support.
The American Diabetes Association 2026 Standards of Care name GLP-1 receptor agonists as the preferred pharmacotherapy for weight management in people with diabetes and overweight or obesity, favoring agents with the greatest weight-loss potential. Both documents are consistent on one point: these medications are tools used inside a broader plan of nutrition, activity and behavioral support, not standalone fixes.
Weight Loss and Heart Health Together
For people who carry excess weight and are concerned about heart and circulation health, the research connecting GLP-1 medications to both weight and cardiovascular outcomes is meaningful. It is one reason medical weight management programs now track more than the scale.
Body composition matters here too, because rapid weight loss can include some lean mass. A Styku 3D scan can show whether weight coming off is fat, muscle or both, which helps the care team adjust protein intake, strength training and the plan as you go.
Discussing GLP-1 and Heart Health in Draper
Thrive EECP in Draper provides medically supervised weight management that includes evaluation, weekly support, body composition tracking and, when appropriate, conversations about GLP-1 medications. The clinic is at 1111 East Draper Parkway, Draper, UT 84020, serving patients from Sandy, South Jordan, Riverton, Herriman, Cottonwood Heights, Midvale, Murray, Lehi, Alpine, Highland, American Fork and surrounding communities.
If you want to understand whether a GLP-1 conversation fits your goals and history, the first step is a free consultation. Call 385-330-0358 or request a consultation online.
Sources & References
Independent, authoritative sources used in this article, linked so you can verify the details yourself. Information here is educational and not a substitute for medical advice.
Want to Explore This Further?
This article is part of the Thrive EECP Health Library in Draper, Utah. If the topic above sounds relevant to you, the next step is a free, no-pressure conversation about your goals.
About the Author
This article was authored and curated by Phil Kim for the Thrive EECP Health Library, with content guidance from the Thrive team. It is educational information, not medical advice, and does not create a patient relationship. Always consult a qualified healthcare professional about your health.
